ALNY News and Press, Alnylam Pharmaceuticals Inc. From 09/06/22

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 11:10 am ET at the Sheraton New ...

Summary Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) said that a phase 2 trial of its RNAi therapeutic cemdisiran for immunoglobulin A nephropathy achieved positive results . Results previously showed that at week 32, cemdisiran demonstrated a clinically meaningful reduction ...

-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo - - Consistent Proteinuria Reduction Seen with Secondary Endpoints - - Cemdi...

Summary Regeneron will report a decline in revenues this year due to the lack of COVID-19 antibody sales. Growth is set to resume in 2023, driven primarily by Dupixent. The oncology business is in the early stages of growth. Eylea has additional opportunities ahead but als...

– Dr. Sigal Brings Decades of Leadership Experience at Biopharmaceutical Companies – – Served as Chief Scientific Officer and a Director of Bristol-Myers Squibb – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeuti...

Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...

Recent research for Alnylam Pharmaceuticals ( NASDAQ: ALNY ) that found rare mutations in a gene expressed in the liver and related to body mass index ( BMI ) could spur development of new treatments for metabolic disorders. Data and analytics company GlobalData w...

– Data from the Patisiran Global Open-Label Extension and the Phase 4 Observational Studies in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy will also be Presented – – Company to Host Conference Call on September 8 at 8:00 a.m. ET to Di...

Alnylam Pharmaceuticals ' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. But now could also ...